Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma
- Department of Radiation Oncology, University of Alabama Medical Center, Birmingham, AL (United States)
- Department of Radiation Oncology, Center for Advanced Medicine Clinical Cancer Center, Stanford, CA (United States)
Over the past several decades, several biomolecules have been investigated for their ability to deliver radiation to cancer cells, but antibodies have been the carriers of choice in systemic targeted radionuclide therapy (STaRT). Two radioimmunotherapy agents that target the CD20 antigen, {sup 131}I-tositumomab and {sup 9}Y-ibritumomab tiuxetan, have been approved by the U.S. Food and Drug Administration for the treatment of patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL), and clinical trials have shown that they are effective as monotherapies in the salvage setting, producing response rates that are often higher and durations of response that are often longer than those with chemotherapy. Escalated doses of these agents can be supported with stem cell transplantation and can produce high rates of complete response and greater survival in patients with relapsed NHL. The quality and duration of responses are greater with radioimmunotherapy when it is used earlier in the course of treatment.
- OSTI ID:
- 20850088
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Vol. 66, Issue 2; Other Information: DOI: 10.1016/j.ijrobp.2006.04.059; PII: S0360-3016(06)01028-5; Copyright (c) 2006 Elsevier Science B.V., Amsterdam, Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
Ongoing investigations and new uses of radioimmunotherapy in the treatment of non-Hodgkin's lymphoma
Comparison of Radiation Dose Estimation for Myeloablative Radioimmunotherapy for Relapsed or Recurrent Mantle Cell Lymphoma using 131I Tositumomab to that of Other Types of Non-Hodgkin's Lymphoma